All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Raajit K. RampalDuring the Acute Leukemia Forum 2021, the AML Hub spoke to Raajit K. Rampal, Memorial Sloan Kettering Cancer Center, New York, US. We asked, How do you treat AML that has evolved from myeloproliferative disorders (MPD)?
How do you treat AML that has evolved from MPD?
Historically, patients who evolve from MPD to AML tend to have the worst prognosis among all AML subtypes due to their genomic profile. In this video, Rampal discusses treatment approaches in this setting. He believes there is an unmet need in this population, so patients with post-MPD AML should be prioritized in clinical trials, where possible.
Your opinion matters
How important to you is the turnaround time for genetic testing in guiding your initial treatment decisions?